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OBSTETRICSAntibiotic prophylaxis for term or near-term
premature rupture of membranes:
metaanalysis of randomized trials
Gabriele Saccone, MD; Vincenzo Berghella, MDOBJECTIVE: The objective of the study was to evaluate the efficacy of following the Preferred Reporting Item for Systematic Reviews and
antibiotic prophylaxis in women with term or near-term premature
rupture of membranes.
STUDY DESIGN: Searches were performed in MEDLINE, OVID,
Scopus, ClinicalTrials.gov, the PROSPERO International Prospec-
tive Register of Systematic Reviews, EMBASE, ScienceDirect.com,
MEDSCAPE, and the Cochrane Central Register of Controlled Trials
with the use of a combination of key words and text words related
to antibiotics, premature rupture of membranes, term, and trials
from inception of each database to September 2014. We included
all randomized trials of singleton gestations with premature
rupture of membranes at 36 weeks or more, who were random-
ized to antibiotic prophylaxis or control (either placebo or no
treatment). The primary outcomes included maternal cho-
rioamnionitis and neonatal sepsis. A subgroup analysis on studies
with latency more than 12 hours was planned. Before data
extraction, the review was registered with the PROSPERO Inter-
national Prospective Register of Systematic Reviews (registration
number CRD42014013928). The metaanalysis was performedFrom the Department of Neuroscience,
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RESULTS: Women who received antibiotics had the same rate of cho-
rioamnionitis (2.7% vs 3.7%; relative risk [RR], 0.73, 95% confidence in-
terval [CI], 0.48e1.12), endometritis (0.4% vs 0.9%; RR, 0.44, 95% CI,
0.18e1.10), maternal infection (3.1% vs 4.6%; RR, 0.48, 95% CI,
0.19e1.21), and neonatal sepsis (1.0% vs 1.4%; RR, 0.69, 95% CI,
0.34e1.39). In the planned subgroup analysis, women with latency longer
than 12hours, who received antibiotics, had a lower rate of chorioamnionitis
(2.9% vs 6.1%; RR, 0.49, 95% CI, 0.27e0.91) and endometritis (0% vs
2.2%; RR, 0.12, 95% CI, 0.02e0.62) compared with the control group.
CONCLUSION: Antibiotic prophylaxis for term or near-term premature
rupture of membranes is not associated with any benefits in either
maternal or neonatal outcomes. In women with latency longer than 12
hours, prophylactic antibiotics are associated with significantly lower
rates of chorioamnionitis by 51% and endometritis by 88%.
Key words: antibiotic prophylaxis, chorioamnionitis, metaanalysis,
neonatal sepsis, premature rupture of membranesCite this article as: Saccone G, Berghella V. Antibiotic prophylaxis for term or near-term premature rupture of membranes: metaanalysis of randomized trials. Am J
Obstet Gynecol 2015;212:627.e1-9.remature rupture of the membra-P nes (PROM), deﬁned as the rupture
of the membranes before the onset of
labor, occurs in approximately 8% ofpregnancies at term (ie, 37 weeks).1
PROM has been associated with increas-
ed risks of infection for both the mother
(eg, chorioamnionitis and endometritis)
and her baby (eg, neonatal sepsis).2
Despite these infectious risks, the
current management of term PROM
does not include prophylactic antibi-
otics, whereas that of preterm PROM (ie,
<34 weeks) does include antibiotics
prophylaxis.2 The recommendation of
antibiotic prophylaxis in preterm PROM
stems from level 1 evidence of their sig-
niﬁcant association with reductions in
chorioamnionitis and neonatal infection
and with prolongation of pregnancy.3
The only recommended management
for termPROMbased on level 1 evidence
is currently induction of labor.2 There is
instead little information about the efﬁ-
cacy of antibiotics in term or near-term
PROM, despite its infectious risks, andMAY 2015 Amerithe evidence regarding their efﬁcacy in
preterm PROM.
The aim of this metaanalysis was to
evaluate the efﬁcacy of antibiotic pro-
phylaxis in women with term or near-
term PROM.
MATERIALS AND METHODS
The research protocol was designed a
priori, deﬁning methods for searching
the literature, including and examining
articles, and extracting and analyzing
data. Searches were performed in MED-
LINE, OVID, Scopus, ClinicalTrials.gov,
the PROSPERO International Prospec-
tive Register of Systematic Reviews,
EMBASE, ScienceDirect.com, MED-
SCAPE, and the Cochrane Central Reg-
ister of Controlled Trials with the use of a
combination of keywords and text words
related to antibiotics, premature rupture
of membranes, term, and trials from thecan Journal of Obstetrics& Gynecology 627.e1
FIGURE 1
Flow diagram of studies
identified in the systematic
review (PRISMA template)
PRISMA, Preferred Reporting Item for Systematic Reviews and
Meta-analyses.
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2014. No restrictions for language or
geographic location were applied.
We included all randomized controlled
trials (RCTs) of singleton gestations with
PROM at 36 weeks or more, who were
randomized to antibiotic prophylaxis or
control (either placebo or no treatment).
All published randomized studies on
antibiotic prophylaxis for patients with
term or near-term PROM were carefully
reviewed. Exclusion criteria included
quasirandomized trials, trials in women
with preterm PROM, trials that were
restricted to only group B streptococcuse
positive women, trials using antibiotics
no longer recommended in pregnancy,
and trials in which antibiotics were used
also in a control group.
Before data extraction, the review
was registered with the PROSPERO In-
ternational Prospective Register of Sys-
tematic Reviews (registration number
CRD42014013928). The metaanalysis
was performed following the Preferred
Reporting Item for Systematic Reviews
andMeta-analyses (PRISMA) statement.4
Data abstraction was completed by 2
independent investigators (G.S. and
V.B.). Each investigator independently
abstracted data from each study and
analyzed the data separately. Differences
were reviewed and further resolved by
common review of the entire data. Au-
thors were contacted for missing data.
The risk of bias in each included study
was assessed by using the criteria outlined
in theCochraneHandbook for Systematic
Reviews of Interventions (The Cochrane
Collaboration’s tool for assessing risk of
bias). Sevendomains related to risk of bias
were assessed in each included trial
because there is evidence that these issues
are associated with the following biased
estimates of treatment effect: (1) random
sequence generation; (2) allocation
concealment; (3) blinding of participants
and personnel; (4) blinding of outcome
assessment; (5) incomplete outcomedata;
(6) selective reporting; and (7) other bias.
Review authors’ judgments were catego-
rized as low risk, high risk, or unclear risk
of bias.5
All analyses were done using an
intention-to-treat approach, evaluating
women according to the treatment group627.e2 American Journal of Obstetrics& Gynecoltowhich they were randomly allocated in
the original trials. The outcomes were
chosen to reﬂect maternal morbidity,
obstetric intervention, and perinatal
morbidity and mortality. Primary out-
comes were maternal chorioamnionitis
and neonatal sepsis (with or without
positive blood cultures).
Maternal secondary outcomes in-
cluded latency, cesarean delivery (CD),
endometritis, postpartum septicemia,
placental abruption, induction of labor,
spontaneous labor, cord prolapse, days of
hospitalization, breast-feeding, and
maternal adverse drug reaction. Sec-
ondary neonatal outcomes included
admission to the neonatal intensive care
unit (NICU), respiratory complications,
abnormality on cerebral ultrasound
(either cystic periventricular leukomala-
cia or intraventricular hemorrhage), ce-
rebral palsy, the rate of neonates who
required antibiotics, neonatal infection/
sepsis, Apgar score less than 7 at 5 mi-
nutes, and perinatal death. Because the
rate of maternal and perinatal infection
increases with longer times from
admission to delivery, a subgroup anal-
ysis on the studies with latency more
than 12 hours was planned.6
The data analysis was completed inde-
pendently by the authors (G.A. and V.B.)
using Review Manager 5.3 (The Nordic
Cochrane Centre, The Cochrane Collab-
oration, Copenhagen, Denmark). The
completed analyses were then compared,
and any difference was resolved with a
review of the entire data and independent
analysis. Statistical heterogeneity between
studies was assessed using the Cochrane
Q statistic and Higgins I2 statistics.
In case of statistical signiﬁcant het-
erogeneity (a value of the Cochrane Q
statistic of P < .1), the random effects
model of DerSimonian and Laird5 was
used to obtain the pooled risk ratio (RR)
estimate; otherwise a ﬁxed-effect models
was planned. The summary measures
were reported as RR with a 95% conﬁ-
dence interval (CI). A value of P < .05
was considered statistically signiﬁcant.
This study had no funding source.
RESULTS
We identiﬁed 8 trials on antibiotic pro-
phylaxis in termor near-termPROM.7-14ogy MAY 2015Three were excluded7-9: 2 were excluded
because they were quasirandomized tri-
als,8,9 and 1 was excluded because the
antibiotic used (tetracycline) is no longer
recommended for use in pregnancy.7
Five trials, which met inclusion criteria
for this metaanalysis, were included.10-14
Figure 1 shows the ﬂow diagram
(PRISMA template) of information
through the different phases of the
review. The authors of one of these
included trials provided the requested
additional information.10
FIGURE 2
Assessment of risk of bias
A, Summary of the risk of bias for each trial. B, Risk of bias graph about each risk of bias item presented as percentages across all included studies. The
minus sign indicates high risk of bias; plus sign indicates low risk of bias; question mark indicates unclear risk of bias.
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TABLE 1
Descriptive data of included trials
Variable
Walss Rodriguez
and Navarro
Castanon, 198814
Cararach
et al, 199811 Ovalle et al, 199810
Passos
et al, 201212
Nabhan
et al, 201413 Total
Study location Mexico Spain Chile Portugal Egypt —
Patients at
randomization, n
60 (30/30) 733 (371/362) 105 (55/50) 161 (78/83) 1640
(820/820)
2699
(1354/1345)
GA at
randomization
(wksdays)
370 360 370e426 370 360 —
GBS status N/A N/A N/A All negative All negative —
Intervention IV penicillin 4 million
U every 4 h or
gentamicin 80 mg
every 8 h for women
with penicillin allergy
IV ampicillin 1 g
every 6 h and IM
gentamicin 80 mg
every 8 h or IM
erythromycin 500 mg
every 6 h for women
with penicillin allergy
IV clindamycin 600 mg
every 6 h and IV
cefuroxime 750 every
8 h. Then oral
cefuroxime 250 mg every
12 h and clindamycin
300 mg every 6 h
IV ampicillin 1 g
every 6 h and IV
gentamicin
240 mg every day
IV 1500 mg
ampicillin
—
Control Placebo No treatment Placebo No treatment Placebo —
Primary outcome Mode of delivery Latency, mode
of delivery,
chorioamnionitis
Chorioamnionitis,
neonatal morbidity
Maternal infection Neonatal sepsis —
Data are presented as total number (n intervention/control).
GA, gestational age; GBS, group B Streptococcus; IM, intramuscularly; IV, intravenous; N/A, not available.
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TABLE 2
Primary and secondary outcomes of included trials
Variable
Walss Rodriguez
and Navarro
Castanon, 198814
Cararach et al,
199811
Ovalle et al,
199810
Passos et al,
201212
Nabhan et al,
201413 Total RR (95% CI)
Latency from admission to delivery
interval, h, mean  SD
N/A N/A N/A 15.0  8.4 vs
14.9  7.9
5.3  3.5 vs
5.4  3.6
— Mean difference,
e0.08 h (e0.41 to
0.26)
Latency from PROM to delivery
interval, h, mean  SD
N/A 15.4  7.3 vs
16.1  9.4
28.1  12.9 vs
23.5  11.2
17.4  8.4 vs
17.3  7.9
N/A — Mean difference,
0.46 h (e1.78 to 2.73)
Cesarean delivery 10/30 vs 8/30 N/A 10/55 vs 7/50 17/78 vs 16/83 165/820 vs
122/820
202/983 (20.5%) vs
153/983 (15.6%)
1.32 (1.09e1.60)
Chorioamnionitis N/A 12/371 vs 17/362 1/55 vs 4/50 2/78 vs 9/83 21/820 vs
19/820
36/1324 (2.7%) vs
49/1315 (3.7%)
0.73 (0.48e1.12)
Endometritis N/A 0/371 vs 4/362 0/55 vs 5/50 0/78 vs 2/83 5/820 vs 2/820 5/1324 (0.4%) vs
13/1315 (0.9%)
0.44 (0.18e1.10)
Induction of labor N/A 136/371 vs 111/362 26/55 vs 23/50 48/78 vs 48/83 513/820 vs
511/820
723/1324 (54.6%) vs
693/1315 (52.7%)
1.04 (0.97e1.11)
Spontaneous labor N/A 230/371 vs 247/362 29/55 vs 27/50 27/78 vs 35/83 N/A 289/504 (57.3%) vs
309/495 (62.4%)
0.91 (0.82e1.00)
Days of hospitalization,
Mean  SD
N/A N/A N/A 2.6  1.7 vs
2.8  1.1
N/A — Mean difference,
e0.20 d (0.43 to 0.26)
Breast-feeding N/A N/A 55/55 vs 50/50 N/A N/A 55/55 (100%) vs
50/50 (100%)
1.00 (0.96e1.04)
Side effects N/A 1/371 vs 0/362 0/55 vs 0/50 N/A 0/820 vs 0/820 1/1246 (0.1%) vs
0/1232 (0%)
2.93 (0.12e71.63)
NICU N/A N/A 0/55 vs 0/50 N/A 43/820 vs 37/820 43/875 (4.9%) vs
37/870 (4.2%)
1.16 (0.76e1.78)
Respiratory complications N/A 10/371 vs 15/362 0/55 vs 0/50 N/A N/A 10/426 (2.3%) vs
15/412 (3.6%)
0.65 (0.30e1.43)
Neonatal antibiotics N/A N/A 1/55 vs 7/50 N/A N/A 1/55 (1.8%) vs
7/50 (14%)
0.13 (0.02e1.02)
Neonatal sepsis N/A 1/371 vs 7/362 0/55 vs 0/50 3/78 vs 5/83 9/820 vs 7/820 13/1324 (1.0%) vs
19/1315 (1.4%)
0.69 (0.34e1.39)
Apgar <7 at 5 min N/A 5/371 vs 5/365 0/55 vs 0/50 N/A 15/820 vs 7/820 20/1246 (1.6%) vs
12/1235 (1.0%)
1.66 (0.81e3.37)
Perinatal death N/A 2/371 vs 2/362 0/55 vs 0/50 0/78 vs 0/83 6/820 vs 2/820 8/1324 (0.6%) vs
4/1315 (0.3%)
1.98 (0.60e6.55)
Data are presented as number intervention vs number control.
CI, confidence interval; N/A, not available; neonatal antibiotics, number of neonates who required antibiotic; NICU, admission to neonatal intensive care unit; PROM, premature rupture of membranes; RR, relative risk.
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FIGURE 3
Forest plot for chorioamnionitis
CI, confidence interval.
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ajog.org Obstetrics ResearchMost studies had a low risk of bias in
allocation concealment and selective
reporting by the Cochrane Collabora-
tion’s tool. Two of the 5 studies were
double blind (Figure 2).
The characteristics of the 5 included
trials are summarized in Table 1. Of
the 2699 women, 1354 (50.1%) were
randomized to the antibiotics group,
whereas 1345 (49.9%) were ran-
domized to the control group. Three
of the 5 studies used a placebo as the
control.
Table 2 show the primary and sec-
ondary outcomes. Given some hetero-
genicity among studies, random-effect
models were used. There was no signif-
icant difference in latency from admis-
sion to delivery and from PROM to
delivery between the 2 groups. Women
who received antibiotics had the same
rate of chorioamnionitis (2.7% vs 3.7%;
RR, 0.73; 95% CI, 0.48e1.12),FIGURE 4
Forest plot for endometritis
CI, confidence interval.
Saccone. Antibiotic prophylaxis for term or near-term prematurendometritis (0.4% vs 0.9%; RR, 0.44;
95% CI, 0.18e1.10), and neonatal sepsis
(1.0% vs 1.4%; RR, 0.69; 95% CI,
0.34e1.39) (Table 2 and Figures 3-5).
There were no differences in all of the
secondary outcomes except for the rate
of cesarean delivery, which was higher in
the antibiotics group compared with the
controls (20.5% vs 15.6%; RR, 1.32; 95%
CI, 1.09e1.60) (Table 2). Only one study
reported data about septicemia,
placental abruption, cord prolapse, ce-
rebral abnormality, and cerebral palsy;
however, they found no case in each
groups about these outcomes.10
In the subgroup analysis, women with
latency longer than 12 hours, who
received antibiotics, had a lower rate of
chorioamnionitis (2.9% vs 6.1%; RR,
0.49; 95% CI, 0.27e0.91) and endome-
tritis (0% vs 2.2%; RR, 0.12; 95% CI,
0.02e0.62) compared with the control
group. No signiﬁcant difference wase rupture of membranes. Am J Obstet Gynecol 2015.
MAY 2015 Amerifound in the other outcomes (Table 3
and Figures 6-8).
Conclusion
This metaanalysis of the 5 RCTs evalu-
ating the efﬁcacy of prophylaxis antibi-
otic treatment in women with term or
near-term PROM shows that antibi-
otics treatment is not associated with the
prevention of maternal chorioamnioni-
tis or endometritis or neonatal sepsis. In
the overall analysis, an increase in ce-
sarean delivery was seen in the antibi-
otics group. A signiﬁcant decrease in
maternal chorioamnionitis and endo-
metritis was found in the subgroup
analysis of the women with latency
longer than 12 hours, with no effect on
the cesarean delivery rates.
Beneﬁts of antibiotics in term or near-
term PROM depend greatly on latency
and so on the timing and length of in-
duction. It has been shown that thecan Journal of Obstetrics& Gynecology 627.e5
FIGURE 5
Forest plot for neonatal sepsis
CI, confidence interval.
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TABLE 3
Subgroup analysis for women with latency longer than 12 h
Variable
Cararach et al,
199811 Ovalle et al, 199810 Passos et al, 201212 Total RR (95% CI)
Cesarean delivery N/A 10/55 vs 7/50 17/78 vs 16/83 27/133 (20.3%) vs
23/133 (17.3%)
1.18 (0.72e1.95)
Chorioamnionitis 12/371 vs 17/362 1/55 vs 4/50 2/78 vs 9/83 15/504 (2.9%) vs
30/495 (6.1%)
0.49 (0.27e0.91)
Endometritis 0/371 vs 4/362 0/55 vs 5/50 0/78 vs 2/83 0/504 (0%) vs
11/495 (2.2%)
0.12 (0.02e0.62)
Induction of labor 136/371 vs 111/362 26/55 vs 23/50 48/78 vs 48/83 210/504 (41.7%) vs
182/495 (36.8%)
1.14 (0.98e1.33)
Spontaneous labor 230/371 vs 247/362 29/55 vs 27/50 27/78 vs 35/83 289/504 (57.3%) vs
309/495 (62.4%)
0.91 (0.82e1.00)
Days of hospitalization,
mean  SD
N/A N/A 2.61.7 vs 2.81.1 N/A Mean difference,
e0.20 days
(e0.43 to 0.26)
Breast-feeding N/A 55/55 vs 50/50 N/A 55/55 (100%) vs
50/50 (100%)
1.00 (0.96e1.04)
Side effects 1/371 vs 0/362 0/55 vs 0/50 N/A 1/426 (0.2%) vs
0/412 (0%)
2.93 (0.12e71.63)
NICU N/A 0/55 vs 0/50 N/A 0/55 (0%) vs
0/50 (0%)
N/E
Respiratory complications 10/371 vs 15/362 0/55 vs 0/50 N/A 10/426 (2.3%) vs
15/412 (3.6%)
0.65 (0.30e1.43)
Neonatal antibiotics N/A 1/55 vs 7/50 N/A 1/55 (1.8%) vs
7/50 (14%)
0.13 (0.02e1.02)
Neonatal sepsis 1/371 vs 7/362 0/55 vs 0/50 3/78 vs 5/83 4/504 (0.8%) vs
12/495 (2.4%)
0.34 (0.11e1.04)
Apgar <7 5/371 vs 5/365 0/55 vs 0/50 N/A 5/426 (1.1%) vs
5/415 (1.2%)
0.98 (0.29e3.37)
Perinatal death 2/371 vs 2/362 0/55 vs 0/50 0/78 vs 0/83 2/504 (0.4%) vs
2/495 (0.4%)
0.98 (0.29e3.37)
Data are presented as number intervention vs number control.
CI, confidence interval; N/A, not available; N/E, not applicable; Neonatal antibiotics, number of neonates who required antibiotic; NICU, admission to neonatal intensive care unit; RR, relative risk.
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FIGURE 6
Forest plot of subgroup analysis for chorioamnionitis
CI, confidence interval.
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ajog.org Obstetrics Researchlonger the latency between term or near-
term PROM and delivery, the higher is
the maternal and perinatal infectious
risk. In fact, rates of chorioamnionitis
and endometritis are increased 2.3-fold,
with latency of more than 12 hours
compared with shorter latency.6
Clinical examples help understand the
role of prophylactic antibiotics for term
or near-term PROM. A woman with
term or near-term PROM and breech
presentation, who immediately receives
a cesarean delivery, will probably not
beneﬁt from prophylactic antibiotics just
for the PROM. Conversely, a woman
with a closed and long cervix presenting
many hours after term or near-term
PROM with a vertex presentation
needing induction may have maternal
and perinatal beneﬁts from prophylactic
antibiotics.
Analyzing our metaanalysis data ac-
cording to length of latency, it can be
seen that in term or near-term PROM,
longer latency is associated with higher
rates of maternal chorioamnionitis andFIGURE 7
Forest plot of subgroup analysis for e
CI, confidence interval.
Saccone. Antibiotic prophylaxis for term or near-term prematurendometritis, as well as neonatal sepsis, if
no prophylactic antibiotics are given
(Figure 9, A). Instead, if prophylactic
antibiotics are given, these rates of
maternal and neonatal infection tend to
remain similar, regardless of length of
latency (Figure 9, B). Clinically, these
data also reinforce the recommendation
for induction as soon as feasible after
term or near-term PROM.
Preventing chorioamnionitis in
women with term or near-term PROM
may have further beneﬁts. In fact, clin-
ical or histological chorioamnionitis has
been associated with cerebral palsy,15 so
clinical strategies to prevent or reduce
rates of chorioamnionitis could poten-
tially lead to a reduction in possible
neurologic long-term consequences.
The increased rate in cesarean
observed in the overall analysis, but not
in the subgroup analysis, is of unclear
explanation and signiﬁcance. However,
women with chorioamnionitis have
been reported to have higher rates of
CD,16 which contradicts an associationndometritis
e rupture of membranes. Am J Obstet Gynecol 2015.
MAY 2015 Ameribetween prophylactic antibiotics and
rates of CD. Rates of cesarean delivery in
our metaanalysis were 20.5% in the an-
tibiotics group and 15.6% in the control
group, rates that are lower than current
US cesarean rates.17 Given these facts, it
is possible that the association between
prophylactic antibiotics and cesarean
delivery in the overall analysis was a
chance ﬁnding.
Another metaanalysis evaluated the
efﬁcacy of antibiotic prophylaxis in term
or near-term PROM.18 However, this
review did not include all currently
available RCTs. It showed that the use of
antibiotics in PROM at term or near
term was associated with a signiﬁcant
reduction in endometritis but not in
chorioamnionitis and neonatal sepsis.
One of the strengths of our study is the
inclusion of only RCTs on antibiotic
prophylaxis in women with term or
near-term PROM. Furthermore, no
prior metaanalysis is up to date and
comprehensive in terms of included
studies, and the number of womencan Journal of Obstetrics& Gynecology 627.e7
FIGURE 8
Forest plot of subgroup analysis for neonatal sepsis
CI, confidence interval.
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Research Obstetrics ajog.orgincluded in our analysis is the highest
among all metaanalyses available. Po-
tential publication bias was assessed by a
visual inspection of the funnel plot, and a
symmetric plot suggested no publication
bias (Figure 10).
Limitations of our study are inherent
to the limitations of the included RCTs.
Only one10 of the included studies had a
low risk of bias in all items according
to the Cochrane’s risk of bias tool. It
appears that the study by Nabhan et al13
provided results that were somewhat
different from the other studies for the
main outcomes. This is probably because
the investigators had the shortest latency
from admission to delivery, only about 5
hours in both group (Table 2). With aFIGURE 9
Incidence of chorioamnionitis, endom
The x-axis indicates the length of latency in hours, a
no treatment. B, Women in the antibiotic prophyla
CI, confidence interval.
Saccone. Antibiotic prophylaxis for term or near-term prematur
627.e8 American Journal of Obstetrics& Gynecolshort latency, the effect of antibiotics
may not be apparent.
Clearly there were similarities among
the studies, apart from inclusion criteria,
patient population, etc. For example, in
all included studies, in the absence of
regular uterine contractions, oxytocin
was given intravenously for induction of
labor. We cannot exclude unreported
differences in management among the
5 included studies, given they were
published over a long time frame
(1988e2014) and in 5 different coun-
tries on 3 different continents. On the
other hand, this increases the external
validity of the metaanalysis. Although no
included study was restricted to only
group B Streptococcus (GBS)-positiveetritis, and neonatal sepsis in length o
nd the y-axis indicates the incidence, in percentage
xis group.
e rupture of membranes. Am J Obstet Gynecol 2015.
ogy MAY 2015women, older studies did not specify
GBS status. Our data can be used pre-
dominantly for women at 37 weeks or
longer; there were no women included at
less than 36 weeks.
Our metaanalysis shows that antibi-
otic prophylaxis in women with term or
near-term PROM is not associated with
beneﬁts in the overall analysis but is
associated with signiﬁcant decreases of
51% in chorioamnionitis and 88% in
endometritis in women with latency
longer than 12 hours. When a patient
presents with term PROM and it is pre-
dicted that the length of latency may be
long (eg, nulliparous woman with a
closed and long cervix), from a practical
clinical perspective, consideration mayf latency
, of infection. A, Women who received placebo or
FIGURE 10
Funnel plot for assessing
publication bias
CI, confidence interval.
Saccone. Antibiotic prophylaxis for term or near-term pre-
mature rupture of membranes. Am J Obstet Gynecol 2015.
ajog.org Obstetrics Researchbe given to starting prophylactic antibi-
otics to decrease chorioamnionitis and
endometritis. Further research is needed
to better predict the length of latency in
term PROM and to evaluate the role of
antibiotics. -
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